Risk factors for adverse outcomes and multidrugresistant Gram-negative bacteraemia in haematology patients with febrile neutropenia in a Singaporean university hospital

Singapore Medical Journal

Volumn 53, Issue 11, 2012, Pages 720-725

  Poon, Li Mei ^a   Jin, Jing ^b   Chee, Yen Lin ^a   Ding, Ying ^c   Lee, Yee Mei ^a   Chng, Wee Joo ^a   Chai, Louis Yi An ^c   Tan, Lip Kun ^a   Hsu, Li Yang ^c  

^a National University Cancer Institute   (Singapore)

^b Centre for Health Services Research   (Singapore)

^c NATIONAL UNIVERSITY HEALTH SYSTEM   (Singapore)

Author keywords

Antimicrobial drug resistance; Empirical antibiotics; Febrile neutropenia; Gram negative bacteraemia; Mortality

Indexed keywords

CARBAPENEM; CASPOFUNGIN; CEFTAZIDIME; FLUCONAZOLE; ITRACONAZOLE; PIPERACILLIN PLUS TAZOBACTAM; POSACONAZOLE; QUINOLONE DERIVATIVE; VANCOMYCIN; VORICONAZOLE;

ACUTE GRANULOCYTIC LEUKEMIA; ADULT; APLASTIC ANEMIA; ARTICLE; BACTERIAL COLONIZATION; EXTENDED SPECTRUM BETA LACTAMASE PRODUCING ENTEROBACTERIACEAE; FEBRILE NEUTROPENIA; FEMALE; GRAM NEGATIVE SEPSIS; HEMATOLOGIC DISEASE; HEMATOPOIETIC STEM CELL TRANSPLANTATION; HUMAN; MAJOR CLINICAL STUDY; MALE; MORTALITY; MULTIDRUG RESISTANCE; MYCOSIS; PREDICTIVE VALUE; PRESCRIPTION; PREVALENCE; PROSPECTIVE STUDY; RISK FACTOR; SENSITIVITY ANALYSIS;

ACADEMIC MEDICAL CENTERS; ADULT; BACTEREMIA; CARBAPENEMS; CEFTAZIDIME; DRUG RESISTANCE, MULTIPLE; FEBRILE NEUTROPENIA; FEMALE; GRAM-NEGATIVE BACTERIA; HUMANS; MALE; MIDDLE AGED; PENICILLANIC ACID; PIPERACILLIN; PREVALENCE; PROSPECTIVE STUDIES; RISK FACTORS; SEPSIS; SINGAPORE; TREATMENT OUTCOME; UNIVERSITIES;

EID: 84870499224     PISSN: 00375675     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (9)

1. Freifeld AG, Bow EJ, Sepkowitz KA, et al. Clinical practice guideline for the use of antimicrobial agents in neutropenic patients with cancer: 2010 update by the Infectious Diseases Society of America. Clin Infect Dis 2011; 52:427-31.
2. Jin J, Lee YM, Ding Y, et al. Prospective audit of febrile neutropenia management at a tertiary university hospital in Singapore. Ann Acad Med Singapore 2010; 39:453-9.
3. Lin MY, Weinstein RA, Hota B. Delay of active antimicrobial therapy and mortality among patients with bacteremia: impact of severe neutropenia. Antimicrob Agents Chemother 2008; 52:3188-94.
4. Bone RC, Balk RA, Cerra FB, et al. Definitions for sepsis and organ failure and guidelines for the use of innovative therapies in sepsis. The ACCP/SCCM Consensus Conference Committee. American College of Chest Physicians/Society of Critical Care Medicine. Chest 1992; 101:1644-55.
5. Klastersky J, Paesmans M, Rubenstein EB, et al. The Multinational Association for Supportive Care in Cancer risk index: a multinational scoring system for identifying low-risk febrile neutropenic cancer patients. J Clin Oncol 2000; 18:3038-51.
6. De Pauw B, Walsh TJ, Donnelly JP, et al. Revised definitions of invasive fungal disease from the European Organization for Research and Treatment of Cancer/Invasive Fungal Infections Cooperative Group and the National Institute of Allergy and Infectious Diseases Mycoses Study Group (EORTC/MSG) Consensus Group. Clin Infect Dis 2008; 46:1813-21.
7. Zeger SL, Liang KY, Albert PS. Models for Longitudinal Data: A Generalized Estimating Equation Approach. Biometrics 1988; 44:1049-60.
8. Lee J, Pai H, Kim YK, et al. Control of extended-spectrum beta-lactamaseproducing Escherichia coli and Klebsiella pneumoniae in a children's hospital by changing antimicrobial agent usage policy. J Antimicrob Chemother 2007; 60:629-37.
9. Paul M, Yahav D, Bivas A, Fraser A, Leibovici L. Anti-pseudomonal beta-lactams for the initial, empirical, treatment of febrile neutropenia: comparison of beta-lactams. Cochrane Database Syst Rev 2010; 11:CD005197.